New Issue: RBC prices $3.02 million 12.75% trigger yield notes linked to Vertex Pharmaceuticals

By Toni Weeks

San Diego, Aug. 9 - Royal Bank of Canada priced $3.02 million of 12.75% annualized trigger yield optimization notes due Feb. 10, 2012 linked to the common stock of Vertex Pharmaceuticals Inc., according to a 424B2 filing with the Securities and Exchange Commission.

Interest will be payable monthly.

The face amount of each note will be equal to the initial price of Vertex stock.

The payout at maturity will be par in cash unless the final price of Vertex stock is less than 75% of the initial share price, in which case investors will receive one Vertex share per note.

UBS Financial Services Inc. and RBC Capital Markets, LLC are the agents.

Issuer:	Royal Bank of Canada
Issue:	Trigger yield optimization notes
Underlying stock:	Vertex Pharmaceuticals Inc. (Symbol: VRTX)
Amount:	$3,018,858
Maturity:	Feb. 10, 2012
Coupon:	12.75%, payable monthly
Price:	Par of $43.00
Payout at maturity:	If final share price is less than trigger price, one Vertex share; otherwise, par
Initial share price:	$43.00
Trigger price:	$32.25, 75% of initial price
Pricing date:	Aug. 5
Settlement date:	Aug. 10
Agents:	UBS Financial Services Inc. and RBC Capital Markets, LLC
Fees:	1%
Cusip:	78010T860

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.